Laboratorios Farmaceuticos ROVI (ROVI.MC) Akcie Kurz
Laboratorios Farmaceuticos ROVI Kurz
Tržby rostly o 12,6 % ročně za posledních 19 let na 743,48 Mil. EUR. Zisk na akcii rostl o 19,0 % ročně za posledních 19 let. čistá marže společnosti Laboratorios Farmaceuticos ROVI je nyní 18,9 %, dolů z 23,6 % před několika lety. Laboratorios Farmaceuticos ROVI aktuálně nabízí dividendový výnos kolem 1,49 %. Výplatní poměr je kolem 34 % zisku. Dividenda rostla o 15,7 % ročně za posledních 17 let. Medián cílové ceny analytiků je 85,07 EUR, tedy nad aktuální cenu o 35,2 %. Z 16 analytiků jich 13 doporučuje nákup — celkový konsenzus je Koupit.
Cena akcie Laboratorios Farmaceuticos ROVI
Tato data přes Eulerpool API
100 000 požadavků/měs. zdarma · bez karty
Obchodní model Laboratorios Farmaceuticos ROVI a analýza akcií
Nejčastější otázky týkající se akcie Laboratorios Farmaceuticos ROVI
The business model of Laboratorios Farmaceuticos ROVI SA focuses on pharmaceutical research, development, manufacturing, and commercialization. The company operates in the specialty pharmaceuticals industry and specializes in the production of injectable pharmaceuticals and various other drugs. Laboratorios Farmaceuticos ROVI SA collaborates with international partners for the licensing and distribution of its products. With a strong emphasis on innovation and quality, the company aims to provide healthcare solutions through its unique product portfolio. Laboratorios Farmaceuticos ROVI SA actively pursues partnerships and collaborations to expand its market reach and continuously improve its product pipeline.
Laboratorios Farmaceuticos ROVI SA is primarily active in the pharmaceutical industry.
The main competitors of Laboratorios Farmaceuticos ROVI SA in the market include pharmaceutical companies such as Novartis, Pfizer, Johnson & Johnson, and Sanofi.
Laboratorios Farmaceuticos ROVI SA is a renowned pharmaceutical company with an impressive history and background. Established in 1946, ROVI SA has consistently focused on developing and manufacturing innovative healthcare solutions. With its headquarters in Madrid, Spain, the company operates in various therapeutic areas, including Special Focused Medicines, Biosimilars, and Active Pharmaceutical Ingredients (APIs). ROVI SA has a strong commitment to research and development, striving to improve patients' quality of life through cutting-edge treatments. Over the years, the company has gained recognition and trust from healthcare practitioners and patients alike, solidifying its position as a prominent player in the pharmaceutical industry.
Laboratorios Farmaceuticos ROVI SA has achieved several significant milestones throughout its history. One noteworthy achievement is its development of innovative pharmaceutical products, including advanced drug delivery systems and therapeutic solutions. The company has also gained recognition for its expertise in biopharmaceutical manufacturing and has successfully established numerous strategic partnerships globally. Additionally, Laboratorios Farmaceuticos ROVI SA has demonstrated consistent growth and profitability, expanding its market presence and enhancing shareholder value. These achievements reflect the company's commitment to delivering high-quality healthcare solutions and driving advancements within the pharmaceutical industry.
Laboratorios Farmaceuticos ROVI SA is primarily present in Spain, where the company is based. Additionally, ROVI has a global presence, with its products and services being available in several other countries and regions around the world. These include various European countries such as Germany, France, Italy, Portugal, and the United Kingdom. Furthermore, ROVI has a significant presence in the Americas, including Mexico, Brazil, and Colombia. With its international reach, Laboratorios Farmaceuticos ROVI SA has established a strong presence in both European and American markets, catering to a wide range of customers and expanding its global footprint.
Laboratorios Farmaceuticos ROVI SA represents values of innovation, integrity, and excellence in the pharmaceutical industry. With a strong corporate philosophy centered on the development and manufacturing of innovative medicines and healthcare products, ROVI prioritizes patient well-being and strives for scientific advancement. The company's commitment to research and development, along with its focus on partnerships with healthcare professionals and organizations, enables ROVI to provide innovative solutions that improve patients' lives. By embracing a culture of responsibility, transparency, and ethical practices, Laboratorios Farmaceuticos ROVI SA aims to contribute to global healthcare and deliver value to its stakeholders.
Analytici aktuálně stanovují průměrnou cílovou cenu 84,26 EUR pro akcii Laboratorios Farmaceuticos ROVI (medián: 85,07 EUR), tedy +34,7 % vůči poslední ceně. Konsensus vychází z 16 hodnocení analytiků.
16 analytiků aktuálně hodnotí akcii Laboratorios Farmaceuticos ROVI: 13 doporučuje koupit, 3 držet a 0 prodat. Pro rok 2026 analytici očekávají u Laboratorios Farmaceuticos ROVI tržby 780,97 Mil. EUR a zisk na akcii 2,93 EUR.
Akcie Laboratorios Farmaceuticos ROVI (ROVI.MC) je kótována na 9 burzách, mimo jiné: London (0ILL.L), SIX (Zürich) (41L.SW), Frankfurt (41L.F), München (41L.MU), Düsseldorf (41L.DU), Madrid (ROVI.MC).
Laboratorios Farmaceuticos ROVI SA is a leading pharmaceutical company specializing in the development and production of biotechnological drugs, vaccines, and generics. The company was founded in Spain in 1946 and has since built an impressive track record. Today, ROVI is a global player with customers in over 80 countries worldwide. ROVI operates in three business segments: Innovation, Generics, and Specialties. In the Innovation segment, the company focuses on biotechnological drugs and vaccines, with a particular emphasis on tissue repair, kidney and liver diseases, and immuno-oncology. The pipeline of Innovation includes a variety of innovative drugs in various stages of clinical development. A significant milestone for the company was the successful approval of Doria®, an inactivated SARS-CoV-2 vaccine for individuals aged 18 years and older. In the Generics segment, ROVI focuses on high-quality generics for various diseases. The company has strong partnerships worldwide, giving it access to a broad network of producers and suppliers. ROVI is an important supplier to the public health sector in many countries. The Specialties segment comprises different products, such as contrast agents for medical imaging, wound care, and non-surgical wrinkle treatment. ROVI's product range includes a variety of drugs and vaccines for different diseases and applications. Some of the most well-known products are Envarsus® for preventing transplant rejection in kidney or liver transplantations, Bemiparin as an anticoagulant for the prevention and treatment of thrombosis, and Hepacare® for the treatment of Hepatitis C, used in countries like Pakistan to reduce the spread of the disease. To meet the growing needs of the healthcare market, ROVI has invested in research and development. The company has expanded its research and development pipeline and works on developing innovative drugs and products. ROVI is also known for investing in partnerships. The company collaborates closely with other bio-pharmaceutical companies and research institutes to develop new drugs. These partnerships also open up new markets and provide access to new technologies. In summary, ROVI SA has been active as a strategic and influential company in the biopharmaceutical world. Investments in research and development, innovation, and partnerships have contributed to ROVI's recognition in the industry. With a wide network of producers and suppliers worldwide and customers in over 80 countries, ROVI is globally present and has established a strong position in the public health sector.
Tržby očekávané za Laboratorios Farmaceuticos ROVI činí 780,97 Mil. EUR. Tato hodnota je založena na aktuálních finančních údajích a odráží výkonnost společnosti.
Zisk očekávané za Laboratorios Farmaceuticos ROVI činí 149,96 Mil. EUR. Čistý zisk odráží ziskovost společnosti po odečtení všech nákladů.
Poměr ceny k zisku (P/E) Laboratorios Farmaceuticos ROVI je aktuálně 21,46. Poměr P/E porovnává aktuální cenu akcie se ziskem na akcii a pomáhá investorům posoudit ocenění akcie Laboratorios Farmaceuticos ROVI.
Poměr ceny k tržbám (P/S) Laboratorios Farmaceuticos ROVI je aktuálně 4,12. Poměr P/S porovnává tržní kapitalizaci s ročními tržbami a slouží jako metrika ocenění akcie Laboratorios Farmaceuticos ROVI.
Score kvality pro Laboratorios Farmaceuticos ROVI je 7/10.
ISIN Laboratorios Farmaceuticos ROVI je ES0157261019. ISIN (International Securities Identification Number) je celosvětově jedinečný identifikátor cenných papírů.
WKN Laboratorios Farmaceuticos ROVI je A0M0GQ. WKN (Wertpapierkennnummer) je šestimístný německý identifikační kód cenného papíru.
Ticker Laboratorios Farmaceuticos ROVI je ROVI.MC. Symbol tickeru se používá k obchodování akcií Laboratorios Farmaceuticos ROVI na burze.
Laboratorios Farmaceuticos ROVI akcie
Laboratorios Farmaceuticos ROVI Peer Group
Laboratorios Farmaceuticos ROVI Ticker
Laboratorios Farmaceuticos ROVI FIGI
Všechny fundamentální údaje o Laboratorios Farmaceuticos ROVI v podrobné analýze
Naše analýzy akcií společnosti Laboratorios Farmaceuticos ROVI zahrnují důležité finanční ukazatele jako obrat, zisk, P/E poměr, P/S poměr, EBIT, stejně jako informace o dividendách. Dále zkoumáme aspekty jako akcie, tržní kapitalizaci, dluhy, vlastní kapitál a závazky společnosti Laboratorios Farmaceuticos ROVI. Pokud hledáte podrobnější informace o těchto tématech, nabízíme vám na našich podstránkách rozsáhlé analýzy: